Crescent Biopharma, Inc. (CBIO) financials · rev $10.8M
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
Crescent Biopharma, Inc. (CBIO) rev $10.8M.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $10.8M | N/A |
| Operating Income | -$152.6M | -$40.0M |
| Net Income | -$153.9M | -$37.9M |
| EPS (Diluted) | N/A | -$0.59 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $240.3M | $11.1M |
| Current Assets | $236.7M | $11.1M |
| Cash & Equivalents | $213.2M | $10.7M |
| PP&E | $846.0K | N/A |
| Total Liabilities | $37.3M | $5.78M |
| Current Liabilities | $36.1M | $5.78M |
| Shareholders' Equity | $203.0M | $5.31M |
| Retained Earnings | -$171.8M | -$494.4M |
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Cash Flow | -$71.5M | -$31.1M |
| CapEx | $919.0K | $9.97K |
| Investing Cash Flow | -$72.9M | $20.0K |
| Financing Cash Flow | $323.0M | $5.40K |
| Net Change in Cash | $178.5M | -$31.1M |
| Free Cash Flow | -$72.5M | -$31.1M |
FAQ
What is CBIO P/E and revenue?
Crescent Biopharma, Inc. (CBIO) rev $10.8M.
What is CBIO revenue?
Crescent Biopharma, Inc. last cached revenue is $10.8M (FY2025).
Is CBIO profitable?
Crescent Biopharma, Inc. last cached net income is -$153.9M (FY2025).
What are CBIO total assets?
Crescent Biopharma, Inc. last cached total assets are $240.3M (FY2025).
What is CBIO free cash flow?
Crescent Biopharma, Inc. last cached free cash flow is -$72.5M (FY2025).
Not investment advice. Cached statements, not a live tape.